-
公开(公告)号:US20230075405A1
公开(公告)日:2023-03-09
申请号:US17795754
申请日:2021-01-29
申请人: HAP2U , UNIVERSITÉ DE LILLE
发明人: Matthieu RUPIN , Pierre GARCIA , Frederic GIRAUD , Christophe GIRAUD-AUDINE , Betty SEMAIL , Michel AMBERG
摘要: The invention relates to a touch interface comprising, on the one hand, an interfacial surface able to generate a haptic-feedback effect in response to a touch of said surface by a user, and, on the other hand, at least one piezoelectric actuator configured to generate, in said interfacial surface, at least one wave of ultrasonic frequency able to endow the particles of this surface with an elliptical movement having a movement component tangential to said surface, which component is denoted ut(t), and a movement component normal to said surface, which component is denoted un(t), wherein said wave of ultrasonic frequency is chosen so that the amplitude Ut of the tangential component ut(t) and the amplitude Un of the normal component un(t) are substantially equal.
-
公开(公告)号:US20220026381A1
公开(公告)日:2022-01-27
申请号:US17297128
申请日:2019-11-26
IPC分类号: G01N24/10
摘要: This invention concerns a method for analysing the ageing stability of a bituminous binder, in particular by reference to its susceptibility to oxidation, by analysing a sample of the bituminous binder by means of electron spin resonance and measuring the integral of the signal of the carbon-centred stable radicals; accelerated ageing of the bituminous binder, comprising: i) heating the bituminous binder, followed by ii) heating the bituminous binder resulting from step i) under pressure; analysing a sample of the aged bituminous binder obtained from step b) by means of electron spin resonance and measuring the integral of the signal of the carbon-centred stable radicals; and comparing the integral of the signal of the carbon-centred stable radicals of the bituminous binder obtained from the first step and that obtained from the previous step.
-
公开(公告)号:US20210324049A1
公开(公告)日:2021-10-21
申请号:US17258891
申请日:2019-07-09
申请人: INSERM (Institut National de La Santé et de la Recherche Médicale) , Institut Pasteur de Lille , Centre National de la Recherche Scientifique (CNRS) , Université de Lille
IPC分类号: C07K16/10 , G01N33/576 , G01N33/535
摘要: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 542 to 555 of SEQ ID NO: 1.
-
公开(公告)号:US20210269510A1
公开(公告)日:2021-09-02
申请号:US17257966
申请日:2019-07-09
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCH MÉDICALE , INSTITUT PASTEUR DE LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ DE LILLE
IPC分类号: C07K16/10 , G01N33/576 , G01N33/558
摘要: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a quasi-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 10 to 23 of SEQ ID NO: 1.
-
5.
公开(公告)号:US20210038545A1
公开(公告)日:2021-02-11
申请号:US16965663
申请日:2019-01-30
申请人: NSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE) , INSTITUT PASTEUR DE LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG , UNIVERSITÉ DE LILLE
发明人: François TROTTEIN , Adeline BARTHELEMY , Valentin SENCIO , Mauro Martins TEIXEIRA , Angelica THOMAZ VIEIRA , Luciana TAVARES
摘要: Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune/inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection post-influenza. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of colonized (IAV microbiota) mice or IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against S. pneumoniae. The present invention thus relates to the use of short-chain fatty acids for the treatment of bacterial superinfections post-influenza.
-
公开(公告)号:US20210017131A1
公开(公告)日:2021-01-21
申请号:US17042806
申请日:2019-03-29
申请人: Centre national de la recherche scientifique , CHRU de Lille , Universite Côte D'Azur , Institut National de la Sante et da la Recherche Medicale (INSERM) , Université de Lille , YNCREA Hauts de France
发明人: Valérie Vouret , Laetitia Douguet , Alina Ghinet , Germain Homerin , Benoît Guy Marie Rigo , Davy Jérémy Baudelet , Xavier Dezitter , Régis Millet , Christophe Furman
IPC分类号: C07D207/16 , C07D401/12 , C07D409/12 , A61K39/395 , A61K31/4439 , A61K31/4025 , A61K31/4015 , A61P1/00 , A61P35/00
摘要: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the prevention and/or treatment of cancer or inflammatory diseases.
-
公开(公告)号:US10736937B2
公开(公告)日:2020-08-11
申请号:US15537596
申请日:2015-12-22
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 , UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES , INSTITUT PASTEUR DE LILLE
摘要: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.
-
公开(公告)号:US20190091683A1
公开(公告)日:2019-03-28
申请号:US16085424
申请日:2016-03-15
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITÉ DE LILLE , ECOLE CENTRALE DE LILLE , SORBONNE UNIVERSITE
发明人: Michaël Aymeric BAUDOIN , Olivier Khalil BOU MATAR-LACAZE , Antoine Jean-Pierre RIAUD , Jean-Louis Pierre THOMAS
摘要: Electroacoustic device having a transducer including a piezoelectric substrate, first and second electrodes of inverse polarity having respective first and second tracks provided on said substrate, the first and second tracks spiraling around a same center (C), the transducer being configured for generating a swirling ultrasonic surface wave in the substrate.
-
9.
公开(公告)号:US20170354709A1
公开(公告)日:2017-12-14
申请号:US15539380
申请日:2015-12-23
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT PASTEUR DE LILLE , UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES , UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2
CPC分类号: A61K38/164 , A61K45/06
摘要: The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide.
-
10.
公开(公告)号:US20170182077A1
公开(公告)日:2017-06-29
申请号:US15118260
申请日:2015-02-13
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT PASTEUR DE LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES , UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2
发明人: Philippe GOSSET , Muriel PICHAVANT , Gaëlle REMY
IPC分类号: A61K31/7032 , A61K39/09 , A61K39/102 , C07K16/28 , A61K45/06
CPC分类号: A61K31/7032 , A61K39/092 , A61K39/102 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K2317/52 , C07K2317/75 , Y02A50/478
摘要: The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one NKT cell agonist.
-
-
-
-
-
-
-
-
-